JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Viking Therapeutics (NASDAQ: NASDAQ:VKTX) has received a reiterated Buy rating and $90.00 price target from H.C. Wainwright, following the announcement of encouraging results from its Phase 1b clinical trial of VK0214.
The trial, aimed at treating X-linked adrenoleukodystrophy (X-ALD), showed that VK0214 was safe and well-tolerated over a 28-day period.
The study, which was a multi-center, double-blind, and placebo-controlled trial, included adult male patients with the adrenomyeloneuropathy (AMN) form of X-ALD. Participants were divided into three groups: a placebo group, a 20 mg VK0214 daily group, and a 40 mg VK0214 daily group.
Notably, gastrointestinal adverse events were less frequent in the VK0214-treated patients (11%) compared to those in the placebo group (33%). Additionally, a severe adverse event of a wrist fracture was reported in the placebo group.
Viking's VK0214 also demonstrated significant reductions in plasma levels of very long-chain fatty acids (VLCFAs), a key biomarker in X-ALD. In particular, patients treated with VK0214 showed a reduction in mean plasma levels of 26 carbon lysophosphatidyl choline (C26:0-LPC), a diagnostic biomarker for the disease.
Moreover, the treatment led to notable decreases in other plasma lipids, including low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and lipoprotein (a) [Lp(a)], after the 28-day treatment course compared to placebo.
The successful trial outcomes offer a strong basis for the continued advancement of the VK0214 program in X-ALD. H.C. Wainwright highlights the significance of the positive safety profile and the reductions in both VLCFAs and lipid markers, emphasizing the potential of VK0214.
In other recent news, Viking Therapeutics has reported positive results from its Phase 1b clinical trial of VK0214, a drug intended for patients with X-linked adrenoleukodystrophy (X-ALD). The treatment was found to be safe and well-tolerated, with significant reductions in very long-chain fatty acids and other plasma lipids observed. The company is considering further steps for VK0214's development.
Additionally, Viking Therapeutics has reported encouraging results from Phase 2 trials of VK2735, an oral treatment for obesity, and VK2809 for NASH and fibrosis. The company's financial standing remains robust, with over $900 million in cash reserves. Analyst firms including Oppenheimer, Morgan Stanley, JPMorgan, and Truist Securities maintain a positive outlook on Viking Therapeutics, emphasizing the potential of VK2735.
Viking Therapeutics is also exploring the potential of VK2735 transitioning to an over-the-counter status, which could attract larger partners looking to enter the obesity market. The company is preparing for an end-of-Phase 2 meeting with the FDA to discuss the registration path for VK2809 and is planning to advance VK2735 into Phase 3 development for obesity.
InvestingPro Insights
Viking Therapeutics' recent positive clinical trial results are reflected in its strong market performance. According to InvestingPro data, the company has seen an impressive 451.89% price total return over the past year, and a 236.59% return year-to-date. This aligns with the optimistic outlook presented in the article and the reiterated Buy rating from H.C. Wainwright.
InvestingPro Tips highlight that Viking Therapeutics holds more cash than debt on its balance sheet and has liquid assets exceeding short-term obligations. These factors could provide the company with financial flexibility to continue advancing its promising drug candidates, including VK0214.
However, it's important to note that Viking is not currently profitable, with a negative operating income of -$124.68 million over the last twelve months. This is consistent with the company's stage of development, as it focuses on advancing its clinical programs.
For investors considering Viking Therapeutics, InvestingPro offers 12 additional tips that could provide further insights into the company's financial health and market position. These additional tips could be particularly valuable given the potential impact of the VK0214 trial results on the company's future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.